Gardasil efficacy data

The summary of product characteristics (SPC) for Gardasil (human papillomavirus [HPV] types 6, 11, 16 and 18) has been updated.

The new SPC includes information on studies that showed Gardasil has cross-protective efficacy in preventing precancerous cervical lesions due to 10 other HPV types, including type 31.

HPV 31 is related to HPV 16 and is the second most common HPV type in Europe causing precancerous cervical lesions after type 16.

Gardasil is licensed for the prevention of premalignant genital lesions (cervical, vulvar and vaginal), cervical cancer and external genital warts (condyloma acuminata) causally related to HPV types 6, 11, 16 and 18.

View Gardasil drug record

Further information: Sanofi Pasteur MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases